Cynata Therapeutics Ltd banner

Cynata Therapeutics Ltd
ASX:CYP

Watchlist Manager
Cynata Therapeutics Ltd Logo
Cynata Therapeutics Ltd
ASX:CYP
Watchlist
Price: 0.295 AUD 1.72% Market Closed
Market Cap: AU$70m

Wall Street
Price Targets

CYP Price Targets Summary
Cynata Therapeutics Ltd

There are no price targets for CYP.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Cynata Therapeutics Ltd Competitors:
Price Targets
NWSA
News Corp
41% Upside
AFYA
Afya Ltd
12% Upside
VRNS
Varonis Systems Inc
69% Upside

Revenue
Forecast

-3% / Year
Past Growth
123% / Year
Estimated Growth
Estimates Accuracy
-86%
Average Miss
-3% / Year
Past Growth
123% / Year
Estimated Growth
Estimates Accuracy
-86%
Average Miss

For the last 13 years the compound annual growth rate for Cynata Therapeutics Ltd's revenue is -3%. The projected CAGR for the next 3 years is 123%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-60%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-60%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYP's stock price target?
Not Available

CYP doesn't have any price targets made by Wall Street professionals.

What is Cynata Therapeutics Ltd's Revenue forecast?
Projected CAGR
123%

For the last 13 years the compound annual growth rate for Cynata Therapeutics Ltd's revenue is -3%. The projected CAGR for the next 3 years is 123%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett